{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T09:43:58Z","timestamp":1745747038758},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Backround<\/jats:title>\n                <jats:p>We describe one of the first cases of a Posterior reversible encephalopathy syndrome (PRES) under tocilizumab as treatment of Giant cell arteritis (GCA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 65-year-old female with known GCA and treatment with Tocilizumab (TCZ) developed a convulsive epileptic seizure for the first time. MRI was suggestive of PRES and an associated left sided occipital hemorrhage. Extensive high blood pressure values were not detected. The patient recovered within a week and no further seizures occurred under anticonvulsive medication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PRES during the treatment with Tocilizumab hasn\u2019t been described in GCA so far. There are single reports of an association between TCZ and PRES in other entities. Thus, a link between interleukin-6 and the integrity of the vasculature could be considered. The clinical consequence should be a stringent blood pressure monitoring in the ambulant setting of patients receiving TCZ.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02231-7","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T05:02:51Z","timestamp":1624338171000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis \u2013 case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Michaela","family":"Butryn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Mewes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Beuing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"2231_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/EB.S21825","volume":"5","author":"P Patil","year":"2013","unstructured":"Patil P, Karia N, Jain S, Dasgupta B. Giant cell arteritis: a review. Eye Brain. 2013;5:23\u201333. https:\/\/doi.org\/10.2147\/EB.S21825.","journal-title":"Eye Brain"},{"issue":"17","key":"2231_CR2","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77(17):1865\u201379. https:\/\/doi.org\/10.1007\/s40265-017-0829-7.","journal-title":"Drugs"},{"issue":"15","key":"2231_CR3","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1056\/NEJMc1711031","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Klearman M, Collinson N. Trial of Tocilizumab in Giant-cell arteritis. N Engl J Med. 2017;377(15):1494\u20135. https:\/\/doi.org\/10.1056\/NEJMc1711031.","journal-title":"N Engl J Med"},{"issue":"1","key":"2231_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40744-019-0139-5","volume":"6","author":"S Gale","year":"2019","unstructured":"Gale S, Trinh H, Tuckwell K, et al. Adverse events in Giant cell arteritis and rheumatoid arthritis patient populations: analyses of Tocilizumab clinical trials and claims data. Rheumatol Ther. 2019;6(1):77\u201388. https:\/\/doi.org\/10.1007\/s40744-019-0139-5.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"2231_CR5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3747\/pdi.2012.00152","volume":"32","author":"EV Hobson","year":"2012","unstructured":"Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int J Int Soc Perit Dial. 2012;32(6):590\u20134. https:\/\/doi.org\/10.3747\/pdi.2012.00152.","journal-title":"Perit Dial Int J Int Soc Perit Dial"},{"issue":"1","key":"2231_CR6","doi-asserted-by":"publisher","first-page":"e2014014","DOI":"10.4084\/MJHID.2014.014","volume":"6","author":"S Apuri","year":"2014","unstructured":"Apuri S, Carlin K, Bass E, Nguyen PT, Greene JN. Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review. Mediterr J Hematol Infect Dis. 2014;6(1):e2014014. https:\/\/doi.org\/10.4084\/MJHID.2014.014.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"15","key":"2231_CR7","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2169\/internalmedicine.48.1926","volume":"48","author":"K Kobayashi","year":"2009","unstructured":"Kobayashi K, Okamato Y, Inoue H, Usui T, Ihara M, KAwamata J, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med. 2009;48(15):1307\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.48.1926.","journal-title":"Intern Med"},{"issue":"10","key":"2231_CR8","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1590\/0004-282X20180093","volume":"76","author":"M Rosa J\u00fanior","year":"2018","unstructured":"Rosa J\u00fanior M, Borges \u00c9I, Fonseca APA, Fiorot JL, Balarini L, Valim V. Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis. Arq Neuropsiquiatr. 2018;76(10):720\u20131. https:\/\/doi.org\/10.1590\/0004-282X20180093.","journal-title":"Arq Neuropsiquiatr"},{"issue":"22","key":"2231_CR9","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1182\/blood.V128.22.5702.5702","volume":"128","author":"AL Garfall","year":"2016","unstructured":"Garfall AL, Lancaster E, Stadtmauer EA, et al. Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-Bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide. Blood. 2016;128(22):5702. https:\/\/doi.org\/10.1182\/blood.V128.22.5702.5702.","journal-title":"Blood"},{"issue":"7","key":"2231_CR10","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3174\/ajnr.A1588","volume":"30","author":"HM Hefzy","year":"2009","unstructured":"Hefzy HM, Bartynski WS, Boardman JF, Lacomis D. Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features. Am J Neuroradiol. 2009;30(7):1371\u20139. https:\/\/doi.org\/10.3174\/ajnr.A1588.","journal-title":"Am J Neuroradiol"},{"issue":"8","key":"2231_CR11","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1007\/s00415-016-8377-8","volume":"264","author":"M Fischer","year":"2017","unstructured":"Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017;264(8):1608\u201316. https:\/\/doi.org\/10.1007\/s00415-016-8377-8.","journal-title":"J Neurol"},{"issue":"6","key":"2231_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s12975-018-0614-2","volume":"9","author":"KG Blecharz-Lang","year":"2018","unstructured":"Blecharz-Lang KG, Wagner J, Fries A, et al. Interleukin 6-mediated endothelial barrier disturbances can be attenuated by blockade of the IL6 receptor expressed in brain microvascular endothelial cells. Transl Stroke Res. 2018;9(6):631\u201342. https:\/\/doi.org\/10.1007\/s12975-018-0614-2.","journal-title":"Transl Stroke Res"},{"issue":"10","key":"2231_CR13","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.4049\/jimmunol.1004026","volume":"186","author":"CC Zhou","year":"2011","unstructured":"Zhou CC, Irani RA, Dai Y, et al. Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J Immunol (Baltimore, Md. 1950). 2011;186(10):6024\u201334. https:\/\/doi.org\/10.4049\/jimmunol.1004026.","journal-title":"J Immunol (Baltimore, Md. 1950)"},{"issue":"3","key":"2231_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/0006-8993(76)90356-5","volume":"115","author":"L Edvinsson","year":"1976","unstructured":"Edvinsson L, Owman C, Sj\u00f6berg NO. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res. 1976;115(3):377\u201393. https:\/\/doi.org\/10.1016\/0006-8993(76)90356-5.","journal-title":"Brain Res"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02231-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T06:03:10Z","timestamp":1635832990000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02231-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2231"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02231-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"20 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The funding note \u201cOpen Access funding enabled and organized by Projekt DEAL\u201d was added. The article has been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB received meeting\/accommodation expenses from Shire and Zambon. EF received honoraria, grant support and meeting\/accommodation expenses from Roche\/Chugai. SW, OB, CM and JN: The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}